{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:23:23Z","timestamp":1772166203817,"version":"3.50.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA235347"],"award-info":[{"award-number":["CA235347"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009451","name":"Osteopathic Heritage Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009451","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001774","name":"New Jersey Health Foundation","doi-asserted-by":"publisher","award":["PC11-21CV"],"award-info":[{"award-number":["PC11-21CV"]}],"id":[{"id":"10.13039\/100001774","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Camden Health Research Initiative"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The Src tyrosine kinase phosphorylates effector proteins to induce expression of the podoplanin (PDPN) receptor in order to promote tumor progression. However, nontransformed cells can normalize the growth and morphology of neighboring transformed cells. Transformed cells must escape this process, called \u201ccontact normalization\u201d, to become invasive and malignant. Contact normalization requires junctional communication between transformed and nontransformed cells. However, specific junctions that mediate this process have not been defined. This study aimed to identify junctional proteins required for contact normalization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Src transformed cells and oral squamous cell carcinoma cells were cultured with nontransformed cells. Formation of heterocellular adherens junctions between transformed and nontransformed cells was visualized by fluorescent microscopy. CRISPR technology was used to produce cadherin deficient and cadherin competent nontransformed cells to determine the requirement for adherens junctions during contact normalization. Contact normalization of transformed cells cultured with cadherin deficient or cadherin competent nontransformed cells was analyzed by growth assays, immunofluorescence, western blotting, and RNA-seq. In addition, Src transformed cells expressing PDPN under a constitutively active exogenous promoter were used to examine the ability of PDPN to override contact normalization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found that N-cadherin (N-Cdh) appeared to mediate contact normalization. Cadherin competent cells that expressed N-Cdh inhibited the growth of neighboring transformed cells in culture, while cadherin deficient cells failed to inhibit the growth of these cells. Results from RNA-seq analysis indicate that about 10% of the transcripts affected by contact normalization relied on cadherin mediated communication, and this set of genes includes PDPN. In contrast, cadherin deficient cells failed to inhibit PDPN expression or normalize the growth of adjacent transformed cells. These data indicate that nontransformed cells formed heterocellular cadherin junctions to inhibit PDPN expression in adjacent transformed cells. Moreover, we found that PDPN enabled transformed cells to override the effects of contact normalization in the face of continued N-Cdh expression. Cadherin competent cells failed to normalize the growth of transformed cells expressing PDPN under a constitutively active exogenous promoter.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Nontransformed cells form cadherin junctions with adjacent transformed cells to decrease PDPN expression in order to inhibit tumor cell proliferation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Plain English Summary<\/jats:title>\n                    <jats:p>Cancer begins when a single cell acquires changes that enables them to form tumors. During these beginning stages of cancer development, normal cells surround and directly contact the cancer cell to prevent tumor formation and inhibit cancer progression. This process is called contact normalization. Cancer cells must break free from contact normalization to progress into a malignant cancer. Contact normalization is a widespread and powerful process; however, not much is known about the mechanisms involved in this process. This work identifies proteins required to form contacts between normal cells and cancer cells, and explores pathways by which cancer cells override contact normalization to progress into malignant cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s12964-021-00817-9","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T06:03:19Z","timestamp":1645077799000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Heterocellular N-cadherin junctions enable nontransformed cells to inhibit the growth of adjacent transformed cells"],"prefix":"10.1186","volume":"20","author":[{"given":"Stephanie A.","family":"Sheehan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward P.","family":"Retzbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongquan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harini","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary S.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,17]]},"reference":[{"key":"817_CR1","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.cellsig.2012.12.004","volume":"25","author":"M Fujii","year":"2013","unstructured":"Fujii M, Honma M, Takahashi H, Ishida-Yamamoto A, Iizuka H. Intercellular contact augments epidermal growth factor receptor (EGFR) and signal transducer and activator of transcription 3 (STAT3)-activation which increases podoplanin-expression in order to promote squamous cell carcinoma motility. Cell Signal. 2013;25:760\u20135.","journal-title":"Cell Signal"},{"key":"817_CR2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/1246","volume":"19","author":"H Honda","year":"1998","unstructured":"Honda H, Oda H, Nakamoto T, Honda Z, Sakai R, Suzuki T, Saito T, Nakamura K, Nakao K, Ishikawa T, et al. Cardiovascular anomaly, impaired actin bundling and resistance to Src-induced transformation in mice lacking p130 Cas. Nat Genet. 1998;19:361\u20135.","journal-title":"Nat Genet"},{"key":"817_CR3","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1074\/jbc.M109.046631","volume":"285","author":"NR Schuh","year":"2010","unstructured":"Schuh NR, Guerrero MS, Schrecengost RS, Bouton AH. BCAR3 regulates Src\/p130 Cas association, Src kinase activity, and breast cancer adhesion signaling. J Biol Chem. 2010;285:2309\u201317.","journal-title":"J Biol Chem"},{"key":"817_CR4","doi-asserted-by":"publisher","first-page":"9649","DOI":"10.1074\/jbc.M109.047696","volume":"285","author":"Y Shen","year":"2010","unstructured":"Shen Y, Chen CS, Ichikawa H, Goldberg GS. SRC induces podoplanin expression to promote cell migration. J Biol Chem. 2010;285:9649\u201356.","journal-title":"J Biol Chem"},{"key":"817_CR5","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1158\/0008-5472.CAN-05-3152","volume":"66","author":"Y Shen","year":"2006","unstructured":"Shen Y, Jia Z, Nagele RG, Ichikawa H, Goldberg GS. SRC uses Cas to suppress Fhl1 in order to promote nonanchored growth and migration of tumor cells. Cancer Res. 2006;66:1543\u201352.","journal-title":"Cancer Res"},{"key":"817_CR6","doi-asserted-by":"publisher","first-page":"6215","DOI":"10.1073\/pnas.0800747105","volume":"105","author":"H Rubin","year":"2008","unstructured":"Rubin H. Cell-cell contact interactions conditionally determine suppression and selection of the neoplastic phenotype. Proc Natl Acad Sci USA. 2008;105:6215\u201321.","journal-title":"Proc Natl Acad Sci USA"},{"key":"817_CR7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0065-230X(08)00006-7","volume":"100","author":"H Rubin","year":"2008","unstructured":"Rubin H. Contact interactions between cells that suppress neoplastic development: can they also explain metastatic dormancy? Adv Cancer Res. 2008;100:159\u2013202.","journal-title":"Adv Cancer Res"},{"key":"817_CR8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/978-94-017-7380-5_12","volume-title":"Intercellular communication and cancer","author":"H Krishnan","year":"2015","unstructured":"Krishnan H, Goldberg GS. Contact normalization or escape from the matrix. In: Kandous M, editor. Intercellular communication and cancer. Heidelberg: Springer-Verlag; 2015. p. 297\u2013342."},{"key":"817_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.semcancer.2004.08.008","volume":"15","author":"AB Glick","year":"2005","unstructured":"Glick AB, Yuspa SH. Tissue homeostasis and the control of the neoplastic phenotype in epithelial cancers. Semin Cancer Biol. 2005;15:75\u201383.","journal-title":"Semin Cancer Biol"},{"key":"817_CR10","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1038\/onc.2009.278","volume":"28","author":"X Li","year":"2009","unstructured":"Li X, Shen Y, Ichikawa H, Antes T, Goldberg GS. Regulation of miRNA expression by Src and contact normalization: effects on nonanchored cell growth and migration. Oncogene. 2009;28:4272\u201383.","journal-title":"Oncogene"},{"key":"817_CR11","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/j.1349-7006.2008.00816.x","volume":"99","author":"X Li","year":"2008","unstructured":"Li X, Jia Z, Shen Y, Ichikawa H, Jarvik J, Nagele RG, Goldberg GS. Coordinate suppression of Sdpr and Fhl1 expression in tumors of the breast, kidney, and prostate. Cancer Sci. 2008;99:1326\u201333.","journal-title":"Cancer Sci"},{"key":"817_CR12","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1158\/0008-5472.CAN-03-2558","volume":"64","author":"DB Alexander","year":"2004","unstructured":"Alexander DB, Ichikawa H, Bechberger JF, Valiunas V, Ohki M, Naus CC, Kunimoto T, Tsuda H, Miller WT, Goldberg GS. Normal cells control the growth of neighboring transformed cells independent of gap junctional communication and SRC activity. Cancer Res. 2004;64:1347\u201358.","journal-title":"Cancer Res"},{"key":"817_CR13","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrc2841","volume":"10","author":"CC Naus","year":"2010","unstructured":"Naus CC, Laird DW. Implications and challenges of connexin connections to cancer. Nat Rev Cancer. 2010;10:435\u201341.","journal-title":"Nat Rev Cancer"},{"key":"817_CR14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.bbamem.2017.06.015","volume":"1860","author":"M Mesnil","year":"2018","unstructured":"Mesnil M, Aasen T, Boucher J, Chepied A, Cronier L, Defamie N, Kameritsch P, Laird DW, Lampe PD, Lathia JD, et al. An update on minding the gap in cancer. Biochim Biophys Acta Biomembr. 2018;1860:237\u201343.","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"817_CR15","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.3390\/ijms21207624","volume":"21","author":"I Kaszak","year":"2020","unstructured":"Kaszak I, Witkowska-Pilaszewicz O, Niewiadomska Z, Dworecka-Kaszak B, Ngosa Toka F, Jurka P. Role of cadherins in cancer\u2014a review. Int J Mol Sci. 2020;21:7624.","journal-title":"Int J Mol Sci"},{"key":"817_CR16","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.yexcr.2017.04.006","volume":"358","author":"A Kourtidis","year":"2017","unstructured":"Kourtidis A, Lu R, Pence LJ, Anastasiadis PZ. A central role for cadherin signaling in cancer. Exp Cell Res. 2017;358:78\u201385.","journal-title":"Exp Cell Res"},{"key":"817_CR17","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1038\/s41388-018-0304-2","volume":"37","author":"AM Mendonsa","year":"2018","unstructured":"Mendonsa AM, Na TY, Gumbiner BM. E-cadherin in contact inhibition and cancer. Oncogene. 2018;37:4769\u201380.","journal-title":"Oncogene"},{"key":"817_CR18","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.3390\/biom10121596","volume":"10","author":"JL Solan","year":"2020","unstructured":"Solan JL, Lampe PD. Src regulation of Cx43 phosphorylation and gap junction turnover. Biomolecules. 2020;10:1596.","journal-title":"Biomolecules"},{"key":"817_CR19","doi-asserted-by":"publisher","first-page":"18914","DOI":"10.1074\/jbc.M608980200","volume":"282","author":"Y Shen","year":"2007","unstructured":"Shen Y, Khusial PR, Li X, Ichikawa H, Moreno AP, Goldberg GS. Src utilizes Cas to block gap junctional communication mediated by connexin43. J Biol Chem. 2007;282:18914\u201321.","journal-title":"J Biol Chem"},{"issue":"20","key":"817_CR20","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1016\/j.yexcr.2007.09.010","volume":"313","author":"M Pahujaa","year":"2007","unstructured":"Pahujaa M, Anikin M, Goldberg GS. Phosphorylation of connexin43 induced by Src: regulation of gap junctional communication between transformed cells. Exp Cell Res. 2007;313(20):4083\u201390.","journal-title":"Exp Cell Res"},{"key":"817_CR21","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.bbrc.2005.05.104","volume":"333","author":"V Valiunas","year":"2005","unstructured":"Valiunas V, Bechberger JF, Naus CC, Brink PR, Goldberg GS. Nontransformed cells can normalize gap junctional communication with transformed cells. Biochem Biophys Res Commun. 2005;333:174\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"817_CR22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/mc.2940110208","volume":"11","author":"GS Goldberg","year":"1994","unstructured":"Goldberg GS, Martyn KD, Lau AF. A connexin 43 antisense vector reduces the ability of normal cells to inhibit the foci formation of transformed cells. Mol Carcinog. 1994;11:106\u201314.","journal-title":"Mol Carcinog"},{"key":"817_CR23","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1038\/onc.2015.382","volume":"35","author":"Y Su","year":"2016","unstructured":"Su Y, Li J, Shi C, Hruban RH, Radice GL. N-cadherin functions as a growth suppressor in a model of K-ras-induced PanIN. Oncogene. 2016;35:3335\u201341.","journal-title":"Oncogene"},{"key":"817_CR24","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1083\/jcb.141.2.515","volume":"141","author":"A Huttenlocher","year":"1998","unstructured":"Huttenlocher A, Lakonishok M, Kinder M, Wu S, Truong T, Knudsen KA, Horwitz AF. Integrin and cadherin synergy regulates contact inhibition of migration and motile activity. J Cell Biol. 1998;141:515\u201326.","journal-title":"J Cell Biol"},{"key":"817_CR25","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1387\/ijdb.041793ld","volume":"48","author":"LD Derycke","year":"2004","unstructured":"Derycke LD, Bracke ME. N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signalling. Int J Dev Biol. 2004;48:463\u201376.","journal-title":"Int J Dev Biol"},{"key":"817_CR26","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ceb.2005.08.009","volume":"17","author":"J Lilien","year":"2005","unstructured":"Lilien J, Balsamo J. The regulation of cadherin-mediated adhesion by tyrosine phosphorylation\/dephosphorylation of beta-catenin. Curr Opin Cell Biol. 2005;17:459\u201365.","journal-title":"Curr Opin Cell Biol"},{"key":"817_CR27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12964-021-00750-x","volume":"19","author":"MA Ortiz","year":"2021","unstructured":"Ortiz MA, Mikhailova T, Li X, Porter BA, Bah A, Kotula L. Src family kinases, adaptor proteins and the actin cytoskeleton in epithelial-to-mesenchymal transition. Cell Commun Signal. 2021;19:67.","journal-title":"Cell Commun Signal"},{"key":"817_CR28","doi-asserted-by":"publisher","first-page":"9045","DOI":"10.18632\/oncotarget.3515","volume":"6","author":"JA Ochoa-Alvarez","year":"2015","unstructured":"Ochoa-Alvarez JA, Krishnan H, Pastorino JG, Nevel E, Kephart D, Lee JJ, Retzbach EP, Shen Y, Fatahzadeh M, Baredes S, et al. Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms. Oncotarget. 2015;6:9045\u201360.","journal-title":"Oncotarget"},{"key":"817_CR29","doi-asserted-by":"publisher","first-page":"12215","DOI":"10.1074\/jbc.C112.446823","volume":"288","author":"H Krishnan","year":"2013","unstructured":"Krishnan H, Ochoa-Alvarez JA, Shen Y, Nevel E, Lakshminarayanan M, Williams MC, Ramirez MI, Miller WT, Goldberg GS. Serines in the intracellular tail of podoplanin (PDPN) regulate cell motility. J Biol Chem. 2013;288:12215\u201321.","journal-title":"J Biol Chem"},{"key":"817_CR30","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.yexcr.2015.04.019","volume":"335","author":"H Krishnan","year":"2015","unstructured":"Krishnan H, Retzbach EP, Ramirez MI, Liu T, Li H, Miller WT, Goldberg GS. PKA and CDK5 can phosphorylate specific serines on the intracellular domain of podoplanin (PDPN) to inhibit cell motility. Exp Cell Res. 2015;335:115\u201322.","journal-title":"Exp Cell Res"},{"key":"817_CR31","doi-asserted-by":"publisher","first-page":"46533","DOI":"10.1074\/jbc.M307526200","volume":"278","author":"GS Goldberg","year":"2003","unstructured":"Goldberg GS, Alexander DB, Pellicena P, Zhang ZY, Tsuda H, Miller WT. Src phosphorylates Cas on tyrosine 253 to promote migration of transformed cells. J Biol Chem. 2003;278:46533\u201340.","journal-title":"J Biol Chem"},{"key":"817_CR32","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1083\/jcb.200305137","volume":"163","author":"X Chen","year":"2003","unstructured":"Chen X, Kojima S, Borisy GG, Green KJ. p120 catenin associates with kinesin and facilitates the transport of cadherin-catenin complexes to intercellular junctions. J Cell Biol. 2003;163:547\u201357.","journal-title":"J Cell Biol"},{"key":"817_CR33","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00432-020-03456-8","volume":"147","author":"KL Hamilton","year":"2021","unstructured":"Hamilton KL, Sheehan SA, Retzbach EP, Timmerman CA, Gianneschi GB, Tempera PJ, Balachandran P, Goldberg GS. Effects of Maackia amurensis seed lectin (MASL) on oral squamous cell carcinoma (OSCC) gene expression and transcriptional signaling pathways. J Cancer Res Clin Oncol. 2021;147:445\u201357.","journal-title":"J Cancer Res Clin Oncol"},{"key":"817_CR34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1039\/9781849733434-00105","volume-title":"Extracellular and intracellular signaling","author":"JAO Alvarez","year":"2011","unstructured":"Alvarez JAO, George C, Krishnan H, Wu X, Goldberg GS. Contact normalization: mechanisms and pathways to biomarkers and chemotherapeutic targets. In: Adams J, editor. Extracellular and intracellular signaling. Cambridge: Royal Society of Chemistry; 2011. p. 105\u201315."},{"key":"817_CR35","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3389\/fonc.2019.00989","volume":"9","author":"W Yu","year":"2019","unstructured":"Yu W, Yang L, Li T, Zhang Y. Cadherin signaling in cancer: its functions and role as a therapeutic target. Front Oncol. 2019;9:989.","journal-title":"Front Oncol"},{"key":"817_CR36","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrc3647","volume":"14","author":"F van Roy","year":"2014","unstructured":"van Roy F. Beyond E-cadherin: roles of other cadherin superfamily members in cancer. Nat Rev Cancer. 2014;14:121\u201334.","journal-title":"Nat Rev Cancer"},{"key":"817_CR37","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.drudis.2018.07.009","volume":"24","author":"H Krishnan","year":"2019","unstructured":"Krishnan H, Miller WT, Blanco FJ, Goldberg GS. Src and podoplanin forge a path to destruction. Drug Discov Today. 2019;24:241\u20139.","journal-title":"Drug Discov Today"},{"key":"817_CR38","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3390\/ijms20030707","volume":"20","author":"M Quintanilla","year":"2019","unstructured":"Quintanilla M, Montero-Montero L, Renart J, Martin-Villar E. Podoplanin in inflammation and cancer. Int J Mol Sci. 2019;20:707.","journal-title":"Int J Mol Sci"},{"key":"817_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jop.13041","volume":"50","author":"FW Mello","year":"2021","unstructured":"Mello FW, Kammer PV, Silva CAB, Parkinson EK, Monteiro L, Warnakulasuriya S, Rivero ERC. Prognostic and clinicopathological significance of podoplanin immunoexpression in oral and oropharyngeal squamous cell carcinoma: a systematic review. J Oral Pathol Med. 2021;50:1\u20139.","journal-title":"J Oral Pathol Med"},{"key":"817_CR40","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.oraloncology.2018.01.011","volume":"78","author":"EP Retzbach","year":"2018","unstructured":"Retzbach EP, Sheehan SA, Nevel EM, Batra A, Phi T, Nguyen ATP, Kato Y, Baredes S, Fatahzadeh M, Shienbaum AJ, Goldberg GS. Podoplanin emerges as a functionally relevant oral cancer biomarker and therapeutic target. Oral Oncol. 2018;78:126\u201336.","journal-title":"Oral Oncol"},{"key":"817_CR41","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/B978-0-12-394311-8.00018-2","volume":"116","author":"A Kourtidis","year":"2013","unstructured":"Kourtidis A, Ngok SP, Anastasiadis PZ. p120 catenin: an essential regulator of cadherin stability, adhesion-induced signaling, and cancer progression. Prog Mol Biol Transl Sci. 2013;116:409\u201332.","journal-title":"Prog Mol Biol Transl Sci"},{"key":"817_CR42","doi-asserted-by":"publisher","first-page":"7947","DOI":"10.1038\/sj.onc.1208161","volume":"23","author":"AB Reynolds","year":"2004","unstructured":"Reynolds AB, Roczniak-Ferguson A. Emerging roles for p120-catenin in cell adhesion and cancer. Oncogene. 2004;23:7947\u201356.","journal-title":"Oncogene"},{"key":"817_CR43","first-page":"9042","volume":"8","author":"Y Jiang","year":"2015","unstructured":"Jiang Y, Liao L, Shrestha C, Ji S, Chen Y, Peng J, Wang L, Liao E, Xie Z. Reduced expression of E-cadherin and p120-catenin and elevated expression of PLC-gamma1 and PIKE are associated with aggressiveness of oral squamous cell carcinoma. Int J Clin Exp Pathol. 2015;8:9042\u201351.","journal-title":"Int J Clin Exp Pathol"},{"key":"817_CR44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.tranon.2018.08.019","volume":"12","author":"D Bianconi","year":"2019","unstructured":"Bianconi D, Herac M, Spies D, Kieler M, Brettner R, Unseld M, Furnkranz K, Famler B, Schmeidl M, Minichsdorfer C, et al. SERPINB7 Expression predicts poor pancreatic cancer survival upon gemcitabine treatment. Transl Oncol. 2019;12:15\u201323.","journal-title":"Transl Oncol"},{"key":"817_CR45","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41586-020-1973-x","volume":"578","author":"SH Tan","year":"2020","unstructured":"Tan SH, Swathi Y, Tan S, Goh J, Seishima R, Murakami K, Oshima M, Tsuji T, Phuah P, Tan LT, et al. AQP5 enriches for stem cells and cancer origins in the distal stomach. Nature. 2020;578:437\u201343.","journal-title":"Nature"},{"key":"817_CR46","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.canlet.2008.01.029","volume":"264","author":"J Woo","year":"2008","unstructured":"Woo J, Lee J, Chae YK, Kim MS, Baek JH, Park JC, Park MJ, Smith IM, Trink B, Ratovitski E, et al. Overexpression of AQP5, a putative oncogene, promotes cell growth and transformation. Cancer Lett. 2008;264:54\u201362.","journal-title":"Cancer Lett"},{"key":"817_CR47","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13058-018-1076-x","volume":"20","author":"V Pelekanou","year":"2018","unstructured":"Pelekanou V, Villarroel-Espindola F, Schalper KA, Pusztai L, Rimm DL. CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers. Breast Cancer Res. 2018;20:154.","journal-title":"Breast Cancer Res"},{"key":"817_CR48","doi-asserted-by":"publisher","first-page":"4329","DOI":"10.1038\/sj.onc.1210226","volume":"26","author":"K Inoue","year":"2007","unstructured":"Inoue K, Mallakin A, Frazier DP. Dmp1 and tumor suppression. Oncogene. 2007;26:4329\u201335.","journal-title":"Oncogene"},{"key":"817_CR49","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1245\/s10434-014-3742-2","volume":"22","author":"J Wang","year":"2015","unstructured":"Wang J, Cai X, Xia L, Zhou J, Xin J, Liu M, Shang X, Liu J, Li X, Chen Z, et al. Decreased expression of FOXJ1 is a potential prognostic predictor for progression and poor survival of gastric cancer. Ann Surg Oncol. 2015;22:685\u201392.","journal-title":"Ann Surg Oncol"},{"key":"817_CR50","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1038\/onc.2012.363","volume":"32","author":"MK Siu","year":"2013","unstructured":"Siu MK, Wong ES, Kong DS, Chan HY, Jiang L, Wong OG, Lam EW, Chan KK, Ngan HY, Le XF, Cheung AN. Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers. Oncogene. 2013;32:3500\u20139.","journal-title":"Oncogene"},{"key":"817_CR51","first-page":"244","volume":"8","author":"F Mohammad Rezaei","year":"2019","unstructured":"Mohammad Rezaei F, Hashemzadeh S, Ravanbakhsh Gavgani R, Hosseinpour Feizi M, Pouladi N, Samadi Kafil H, Rostamizadeh L, Kholghi Oskooei V, Taheri M, Sakhinia E. Dysregulated KDR and FLT1 gene expression in colorectal cancer patients. Rep Biochem Mol Biol. 2019;8:244\u201352.","journal-title":"Rep Biochem Mol Biol"},{"key":"817_CR52","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.7150\/ijbs.39958","volume":"16","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Yan WT, Yang ZY, Li YL, Tan XN, Jiang J, Zhang Y, Qi XW. The role of WT1 in breast cancer: clinical implications, biological effects and molecular mechanism. Int J Biol Sci. 2020;16:1474\u201380.","journal-title":"Int J Biol Sci"},{"key":"817_CR53","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/bies.20403","volume":"28","author":"H Rubin","year":"2006","unstructured":"Rubin H. What keeps cells in tissues behaving normally in the face of myriad mutations? BioEssays. 2006;28:515\u201324.","journal-title":"BioEssays"},{"key":"817_CR54","doi-asserted-by":"publisher","first-page":"dmm029447","DOI":"10.1242\/dmm.029447","volume":"11","author":"VS LeBleu","year":"2018","unstructured":"LeBleu VS, Kalluri R. A peek into cancer-associated fibroblasts: origins, functions and translational impact. Dis Model Mech. 2018;11:dmm029447.","journal-title":"Dis Model Mech"},{"key":"817_CR55","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","volume":"25","author":"AD Rhim","year":"2014","unstructured":"Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014;25:735\u201347.","journal-title":"Cancer Cell"},{"key":"817_CR56","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","volume":"25","author":"BC Ozdemir","year":"2014","unstructured":"Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014;25:719\u201334.","journal-title":"Cancer Cell"},{"key":"817_CR57","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/bs.ircmb.2015.01.009","volume":"317","author":"J Renart","year":"2015","unstructured":"Renart J, Carrasco-Ramirez P, Fernandez-Munoz B, Martin-Villar E, Montero L, Yurrita MM, Quintanilla M. New insights into the role of podoplanin in epithelial-mesenchymal transition. Int Rev Cell Mol Biol. 2015;317:185\u2013239.","journal-title":"Int Rev Cell Mol Biol"},{"key":"817_CR58","doi-asserted-by":"publisher","first-page":"e78644","DOI":"10.1371\/journal.pone.0078644","volume":"9","author":"S Zhao","year":"2014","unstructured":"Zhao S, Fung-Leung WP, Bittner A, Ngo K, Liu X. Comparison of RNA-Seq and microarray in transcriptome profiling of activated T cells. PLoS ONE. 2014;9:e78644.","journal-title":"PLoS ONE"},{"key":"817_CR59","doi-asserted-by":"publisher","first-page":"e41845","DOI":"10.1371\/journal.pone.0041845","volume":"7","author":"JA Ochoa-Alvarez","year":"2012","unstructured":"Ochoa-Alvarez JA, Krishnan H, Shen Y, Acharya NK, Han M, McNulty DE, Hasegawa H, Hyodo T, Senga T, Geng JG, et al. Plant lectin can target receptors containing sialic Acid, exemplified by podoplanin, to inhibit transformed cell growth and migration. PLoSONE. 2012;7:e41845.","journal-title":"PLoSONE"},{"key":"817_CR60","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/cas.13580","volume":"109","author":"H Krishnan","year":"2018","unstructured":"Krishnan H, Rayes J, Miyashita T, Ishii G, Retzbach EP, Sheehan SA, Takemoto A, Chang YW, Yoneda K, Asai J, et al. Podoplanin: an emerging cancer biomarker and therapeutic target. Cancer Sci. 2018;109:1292\u20139.","journal-title":"Cancer Sci"},{"key":"817_CR61","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.oraloncology.2011.06.508","volume":"47","author":"M Kreppel","year":"2011","unstructured":"Kreppel M, Drebber U, Wedemeyer I, Eich HT, Backhaus T, Zoller JE, Scheer M. Podoplanin expression predicts prognosis in patients with oral squamous cell carcinoma treated with neoadjuvant radiochemotherapy. Oral Oncol. 2011;47:873\u20138.","journal-title":"Oral Oncol"},{"key":"817_CR62","first-page":"1","volume":"96","author":"A Wicki","year":"2007","unstructured":"Wicki A, Christofori G. The potential role of podoplanin in tumour invasion. BrJCancer. 2007;96:1\u20135.","journal-title":"BrJCancer"},{"key":"817_CR63","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ccr.2006.03.010","volume":"9","author":"A Wicki","year":"2006","unstructured":"Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell. 2006;9:261\u201372.","journal-title":"Cancer Cell"},{"issue":"3","key":"817_CR64","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1158\/2326-6066.CIR-15-0060","volume":"4","author":"S Shiina","year":"2016","unstructured":"Shiina S, Ohno M, Ohka F, Kuramitsu S, Yamamichi A, Kato A, Motomura K, Tanahashi K, Yamamoto T, Watanabe R, et al. CAR T cells targeting podoplanin reduce orthotopic glioblastomas in mouse brains. Cancer Immunol Res. 2016;4(3):259\u201368.","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"817_CR65","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1111\/j.1349-7006.2012.02377.x","volume":"103","author":"K Motomura","year":"2012","unstructured":"Motomura K, Natsume A, Watanabe R, Ito I, Kato Y, Momota H, Nishikawa R, Mishima K, Nakasu Y, Abe T, et al. Immunohistochemical analysis-based proteomic subclassification of newly diagnosed glioblastomas. Cancer Sci. 2012;103(10):1871\u20139.","journal-title":"Cancer Sci"},{"key":"817_CR66","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/NEN.0000000000000150","volume":"74","author":"K Kolar","year":"2015","unstructured":"Kolar K, Freitas-Andrade M, Bechberger JF, Krishnan H, Goldberg GS, Naus CC, Sin WC. Podoplanin: a marker for reactive gliosis in gliomas and brain injury. J Neuropathol Exp Neurol. 2015;74:64\u201374.","journal-title":"J Neuropathol Exp Neurol"},{"key":"817_CR67","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/gcc.20808","volume":"49","author":"MA Cortez","year":"2010","unstructured":"Cortez MA, Nicoloso MS, Shimizu M, Rossi S, Gopisetty G, Molina JR, Carlotti C Jr, Tirapelli D, Neder L, Brassesco MS, et al. miR-29b and miR-125a regulate podoplanin and suppress invasion in glioblastoma. Genes Chromosomes Cancer. 2010;49:981\u201390.","journal-title":"Genes Chromosomes Cancer"},{"issue":"6","key":"817_CR68","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/DAD.0000000000001561","volume":"42","author":"YME Neinaa","year":"2019","unstructured":"Neinaa YME, El-Ashmawy AA, Alshenawy HA, Dorgham WL. The prognostic value of podoplanin expression in nonmelanoma skin cancers: correlation with lymphatic vessel density. Am J Dermatopathol. 2019;42(6):432\u20138.","journal-title":"Am J Dermatopathol"},{"issue":"11","key":"817_CR69","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.3390\/cells9112529","volume":"9","author":"S Kamoto","year":"2020","unstructured":"Kamoto S, Shinada M, Kato D, Yoshimoto S, Ikeda N, Tsuboi M, Yoshitake R, Eto S, Hashimoto Y, Takahashi Y, et al. Phase I\/II clinical trial of the anti-podoplanin monoclonal antibody therapy in dogs with malignant melanoma. Cells. 2020;9(11):2529.","journal-title":"Cells"},{"key":"817_CR70","doi-asserted-by":"publisher","first-page":"5265","DOI":"10.21873\/anticanres.11097","volume":"36","author":"IM Cobec","year":"2016","unstructured":"Cobec IM, Sas I, Pirtea L, Cimpean AM, Moatar AE, Ceausu RA, Raica M. Podoplanin as key player of tumor progression and lymph vessel proliferation in ovarian cancer. Anticancer Res. 2016;36:5265\u201372.","journal-title":"Anticancer Res"},{"key":"817_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2020.12.020","volume":"153","author":"J Suzuki","year":"2021","unstructured":"Suzuki J, Aokage K, Neri S, Sakai T, Hashimoto H, Su Y, Yamazaki S, Nakamura H, Tane K, Miyoshi T, et al. Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma. Lung Cancer. 2021;153:1\u201310.","journal-title":"Lung Cancer"},{"issue":"4","key":"817_CR72","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/cas.13190","volume":"108","author":"S Takeuchi","year":"2017","unstructured":"Takeuchi S, Fukuda K, Yamada T, Arai S, Takagi S, Ishii GI, Ochiai A, Iwakiri S, Itoi K, Uehara H, et al. Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation. Cancer Sci. 2017;108(4):696\u2013703.","journal-title":"Cancer Sci"},{"key":"817_CR73","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1158\/1078-0432.CCR-14-0846","volume":"21","author":"T Yoshida","year":"2015","unstructured":"Yoshida T, Ishii G, Goto K, Neri S, Hashimoto H, Yoh K, Niho S, Umemura S, Matsumoto S, Ohmatsu H, et al. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation. Clin Cancer Res. 2015;21:642\u201351.","journal-title":"Clin Cancer Res"},{"key":"817_CR74","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1111\/cas.14891","volume":"112","author":"T Ukaji","year":"2021","unstructured":"Ukaji T, Takemoto A, Shibata H, Kakino M, Takagi S, Katayama R, Fujita N. Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agents. Cancer Sci. 2021;112:2299\u2013313.","journal-title":"Cancer Sci"},{"key":"817_CR75","doi-asserted-by":"publisher","first-page":"33322","DOI":"10.18632\/oncotarget.26055","volume":"9","author":"T Ukaji","year":"2018","unstructured":"Ukaji T, Takemoto A, Katayama R, Takeuchi K, Fujita N. A safety study of newly generated anti-podoplanin-neutralizing antibody in cynomolgus monkey (Macaca fascicularis). Oncotarget. 2018;9:33322\u201336.","journal-title":"Oncotarget"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-021-00817-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-021-00817-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-021-00817-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T22:04:48Z","timestamp":1666649088000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-021-00817-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["817"],"URL":"https:\/\/doi.org\/10.1186\/s12964-021-00817-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-93851\/v1","asserted-by":"object"}]},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,17]]},"assertion":[{"value":"21 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GSG has board membership, intellectual property, and ownership in Sentrimed, Inc. which is developing agents that target PDPN to treat diseases including cancer and arthritis. Other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}